Apatinib Combined With Oral Etoposide in Metastatic HER2 Negative Breast Cancer
NCT03535961
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
32
Enrollment
OTHER
Sponsor class
Conditions
Breast Cancer
Interventions
DRUG:
apatinib+oral etoposide
Sponsor
Chinese Academy of Medical Sciences